Legend Biotech CorpLEGNEarnings & Financial Report
GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a China–based biotech company. It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. The company mainly provides life science research application instruments and services. It was listed on the Hong Kong Stock Exchange in 2015. The current rotating CEO of the firm is Shao Weihui, who also served as the chief operating officer and Chinese Communist Party ...
LEGN Q3 FY2025 Key Financial Metrics
Revenue
$272.3M
Gross Profit
$159.1M
Operating Profit
$-43.5M
Net Profit
$-39.7M
Gross Margin
58.4%
Operating Margin
-16.0%
Net Margin
-14.6%
YoY Growth
70.0%
EPS
$-0.11
Legend Biotech Corp Q3 FY2025 Financial Summary
Legend Biotech Corp reported revenue of $272.3M (up 70.0% YoY) for Q3 FY2025, with a net profit of $-39.7M (up 68.3% YoY) (-14.6% margin). Cost of goods sold was $113.3M, operating expenses totaled $202.5M.
Key Financial Metrics
| Total Revenue | $272.3M |
|---|---|
| Net Profit | $-39.7M |
| Gross Margin | 58.4% |
| Operating Margin | -16.0% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Legend Biotech Corp Q3 FY2025 revenue of $272.3M breaks down across 2 segments, led by Goods Or Services Transferred At Point In Time at $261.8M (96.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Goods Or Services Transferred At Point In Time | $261.8M | 96.2% |
| Goods Or Services Transferred Over Time | $10.5M | 3.8% |
Legend Biotech Corp Revenue by Segment — Quarterly Trend
Legend Biotech Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Goods Or Services Transferred At Point In Time and Goods Or Services Transferred Over Time) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 |
|---|---|---|---|---|
| Goods Or Services Transferred At Point In Time | $261.8M | $239.7M | $185.7M | — |
| Goods Or Services Transferred Over Time | $10.5M | $15.4M | $9.3M | — |
Legend Biotech Corp Quarterly Revenue & Net Profit History
Legend Biotech Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $272.3M | +70.0% | $-39.7M | -14.6% |
| Q2 FY2025 | $255.1M | +36.7% | $-125.4M | -49.2% |
| Q1 FY2025 | $195.1M | +107.5% | $-100.9M | -51.7% |
| Q3 FY2024 | $160.2M | +66.9% | $-125.3M | -78.2% |
| Q2 FY2024 | $186.5M | +154.4% | $-18.2M | -9.8% |
| Q1 FY2024 | $94.0M | +158.7% | $-59.8M | -63.6% |
| Q3 FY2023 | $96.0M | — | $-62.2M | -64.8% |
| Q2 FY2023 | $73.3M | — | $-199.1M | -271.6% |
Income Statement
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.3M | $96.0M | $94.0M | $186.5M | $160.2M | $195.1M | $255.1M | $272.3M |
| YoY Growth | N/A | N/A | 158.7% | 154.4% | 66.9% | 107.5% | 36.7% | 70.0% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.93B | $1.84B | $1.78B | $1.80B | $1.74B | $1.62B | $1.69B | $1.71B |
| Liabilities | $523.6M | $499.7M | $611.0M | $639.2M | $619.7M | $597.9M | $654.4M | $701.7M |
| Equity | $1.41B | $1.34B | $1.16B | $1.16B | $1.12B | $1.02B | $1.04B | $1.01B |
Cash Flow
| Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-97.6M | $-60.8M | $15.5M | $-1.7M | $-75.8M | $-103.8M | $-13.0M | $28.8M |